Benperidol (Anquil) is a butanone analog with antipsychotic and stabilizing properties, and has been shown to be effective in blocking D2 receptors.Benperidol can be used in positron emission tomography (PET) scanning to measure D(2) dopamine receptor binding in vivo.Benperidol has been shown to be effective in blocking D2 receptors in vivo.Benperidol has been shown to be effective in blocking D2 receptors in vivo.

MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs). MK-6240 exhibits high specificity and selectivity for binding to NFTs.

DOTATATE, a DOTA-conjugated peptide, is utilized for its ability to be labeled with radionuclides, facilitating positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT)[4].

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.

FAP-2286 is a peptidic macrocycle that binds to the fibroblast activation protein (FAP) and is linked to the chelator DOTA, facilitating its role as a tumor imaging agent in positron emission tomography (PET) research. Exhibiting strong affinity for the human FAP protein with a dissociation constant (Kd) of 1.1 nM, FAP-2286 demonstrates significant antitumor activity, as referenced in [1] [2].

Omburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.

[Lys3]-Bombesin is a biologically active peptide used in PET (Positron Emission Tomography) imaging to identify GRPR (gastrin-releasing peptide receptor) positive prostate cancer. The compound, when conjugated with a corresponding monoclonal antibody, can selectively trigger CD64-dependent monocyte and neutrophil-mediated lysis in small cell carcinoma.

Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission tomography (PET) imaging [1].

MK-9470 is a selective, high-affinity reverse agonist and is also a fluorine 18 labeled positron emission tomography (PET) radiotracer [(18) F]. The MK-9470 has been used to image cannabinoid receptor type 1 in healthy and ill human brains.

Fet F-18 is an amino acid analog radiolabeled with fluorine F-18, a positron-emitting isotope, can be used as a tracer in positron emission tomography (PET).

JZP-MA-11 is a positron emission tomography (PET) ligand that specifically targets the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. It exhibits selective inhibition of ABHD6, achieving an IC50 value of 126 nM and is capable of crossing the blood-brain barrier (BBB). The compound, labeled with [18F], demonstrates promising potential for preclinical evaluation in both mice and nonhuman primates (NHP) as a tool for investigating brain ABHD6 activity [1].

M1 ligand 1 (compound 3b-b) is a N-desmethyl congener of arecoline derivative that is a muscarinic acetylcholine receptor M1 ligand. M1 ligand 1 is able to be used as PET (positron emission tomography) radiotracer [1].

Altanserin can binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain.

Fluoroethylnormemantine hydrochloride, a Memantine derivative, functions as an antagonist for the N-methyl-D-aspartate (NMDA) receptor. It can also serve as a positron emission tomography (PET) tracer, specifically as [18F]-Fluoroethylnormemantine hydrochloride. Notably, this compound displays a range of effects, including anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.

GSK931145 is a positron emission tomography (PET) radioligand, it is suitable for quantifying glycine transporter (GlyT1) availability in the living brain.

Mppf F-18, which has been used as a radioactive ligand for positron emission tomography, is a compound that binds to the serotonin-1A receptor.

DOTA-NHS-ester is a linker of affibody molecules for small animal PET, SPECT and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for tumor detection.

UCB-J is a radioligand for the synaptic vesicle protein 2A (SV2A), utilized in positron emission tomography (PET)[4].

Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH, also known as Fmoc-Asn(Ac3AcNH-beta-Glc)-OH, is a chemical compound used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, which serve as tumor imaging agents, are valuable tools for positron emission tomography (PET) research.

FAPI-74 is a PET (positron emission tomography) tracer involved in early FAPI-PET imaging.FAPI-74 can be used to study cancerous tumors and degenerative diseases.

LMI-1195 is a 18F-labeled ligand for the norepinephrine transporter. LMI-1195 is used for mapping cardiac nerve terminals in vivo using positron emission tomography (PET).

PBR28, a TSPO modulator, holds potential for preventative research in Pulmonary Arterial Hypertension (PAH) and is instrumental in brain positron emission tomography (PET) imaging studies through its capacity for radioactive labeling to trace the 18 KDa transporter (TSPO) [1].

Altanserin tartrate is a compound that binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain.

JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor, demonstrating impressive specificity with an IC50 value of 392 nM, and exhibits no inhibitory effects on monoacylglycerol lipase (MAGL), ABHD12, fatty acid amide hydrolase (FAAH), or other serine hydrolases. Additionally, JZP-MA-13 serves as a positron emission tomography (PET) ligand for in vivo imaging of ABHD6.

PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.

ML 10 is is a [18F] positron emission tomography (PET) radiotracer that accumulates in cells presenting apoptosis-specific membrane alterations. [18F]ML-10 allows for the detection of apoptotic cells located in atherosclerotic plaques.

DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope F 18 with potential prostate tumor imaging upon positron emission tomogra

Fluoroethylnormemantine, a derivative of Memantine, acts as an N-methyl-D-aspartate (NMDA) receptor antagonist. It can function as a positron emission tomography (PET) tracer, known as [18F]-fluoroethylnormemantine. This compound displays anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.

T807 (AV-1451) is a novel tracer of tau positron emission tomography (PET).

L-FMAC F-18 has potential diagnostic activity during positron emission tomography (PET) imaging. After phosphorylation by DCK, the 18F moiety can be visualized by PET imaging.

PSMA-IN-3 (compound 17) is a novel, high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA) with an inhibitory concentration (IC50) of 13 nM, showing potential for the development of an 18F-labeled radioligand for positron emission tomography (PET) imaging of PSMA in prostate cancer [1].

Lissamine rhodamine B, a new Radiotracer, is used for Imaging Tumors by Positron Emission Tomography.

THK-5105, an arylquinoline derivative, demonstrates a high binding affinity for tau fibrils, protein aggregates, and tau-rich Alzheimer's disease (AD) brain homogenates, indicative of its potential as a tau imaging PET (Positron Emission Tomography) probe with the radiolabeled version, 18F-THK-5105 [1].

CB2 PET Radioligand 1 (compound [18F]9) is a positron emission tomography (PET) radioligand with high affinity for the human cannabinoid receptor 2 (hCB2, Ki=7.7 nM). It is synthesized via Cu-mediated 18F-fluorination and demonstrates significant brain uptake in a mouse model of neuroinflammation [1].

C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabolic stability, and pharmacokinetic profiles. When labeled with [18F] (compound [18F]3), C-ABL-IN-5 serves as a tracer in positron emission tomography (PET) scans to assess disease-modifying effects, particularly in research on neurodegenerative conditions like Parkinson's disease (PD) [1].

HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).

(18F)LBT 999 is a positron emission tomography (PET) tracer, used for the quantification of the dopamine transporter (DAT) in the healthy rat brain.

DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM). It is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. [18F]DPA-714 successfully assesses

N-Descyclopropanecarbaldehyde Olaparib, an Olaparib analogue, incorporates a DOTA moiety. It acts as a CRBN-based ligand for the formation of novel dual EGFR and PARP PROTAC, DP-C-4[1]. N-Descyclopropanecarbaldehyde Olaparib is suitable for radiolabeling with F-18 or a fluorophore to visualize tumors using positron emission tomography (PET) or optical imaging[2].

Melanoma is a lethal skin cancer. The early detection of melanoma using positron emission tomography (PET) probes is critical for improving the survival of melanoma patients. Melanin probe-2 is a non-radioactive bromo-picolinamide precursor that has been used for the synthesis of18F-picolinamides based PET probe (melanin probe-1). The tumor-targeting efficacy and imaging property of three melanin probes were evaluated in B16F10 tumor-bearing mice.18F-1 and18F-3 had much lower tumor uptake compared with18F-2 (Melanin probe-2), which were 12.74 ± 1.70, 16.61 ± 2.60, and 16.87 ± 1.23 %ID/g at 0.5, 1, and 2 h, respectively[1].